NICE review does not recommend routine funding for Duchenne muscular dystrophy gene therapy ataluren in draft guidance

30 September 2022 - NICE has today published draft guidance for public consultation which does not recommend ataluren (Translarna, PTC Therapeutics) ...

Read more →

News “hyperbole” in Government media releases on new drugs can undermine confidence in NHS, says editor

28 September 2022 - Phrases such as “cutting edge,” “game changing,” and “ground breaking” have no place in the description ...

Read more →

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

28 September 2022 - NICE has published evidence-based recommendations on the use of atezolizumab for adjuvant treatment of adults with ...

Read more →

NICE recommends NHS collects real world evidence on devices that monitor people with Parkinson’s disease

27 September 2022 - Five promising technologies that could help improve symptoms and quality of life for people with Parkinson’s disease ...

Read more →

Janssen's Imbruvica passes reimbursement review, BeiGene's Brukinsa fails

22 September 2022 - Janssen's Imbruvica (ibrutinib) and BeiGene's Brukinsa (zanubrutinib), the two BTK (Bruton tyrosine kinase) inhibitors with the ...

Read more →

1,500 people set to receive new skin cancer treatment that reduces the risk of it returning and spreading

23 September 2022 - Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also ...

Read more →

NICE approves routine use of drug combination for advanced breast cancer

23 September 2022 - Another life-extending drug combination for some people with advanced breast cancer will now be available for routine ...

Read more →

Vedolizumab for the treatment of patients with chronic refractory pouchitis

21 September 2022 - NICE is unable to make a recommendation about the use in the NHS of vedolizumab for the ...

Read more →

CADTH recommendation to not reimburse new treatment a failure for people living with schizophrenia

21 September 2022 - The Schizophrenia Society of Canada is joined by the schizophrenia community across Canada in its disappointment with ...

Read more →

CHMP adopts positive opinion for Mycapssa for the treatment of acromegaly

16 September 2022 - Positive opinion based on MPOWERED Phase 3 trial. ...

Read more →

NICE recommends BeiGene’s Brukinsa (zanubrutinib) for patients with Waldenström’s macroglobulinaemia who have had at least one treatment

19 September 2022 - Brukinsa Is the first Bruton’s tyrosine kinase inhibitor recommended by NICE for routine use for Waldenström’s macroglobulinaemia. ...

Read more →

AbbVie secures positive CHMP opinion for risankizumab (Skyrizi) for the treatment of adults with moderate to severe Crohn's disease

19 September 2022 - CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one ...

Read more →

Registry-based randomised trials: the best of both worlds?

15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...

Read more →

Highlights from the 12-15 September 2022 CHMP meeting

16 September 2022 - 12 new medicines recommended for approval. ...

Read more →

Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19

16 September 2022 - Recommendation based on TACKLE Phase 3 treatment data showing reduced risk of severe COVID-19 or death. ...

Read more →